Sleep disturbances (SDs) are among the most distressing and commonly reported symptoms in posttraumatic stress disorder (PTSD). Despite increased attention on sleep in clinical PTSD research, SDs remain difficult to treat. In Phase 2 trials, 3,4-methylenedioxymethamphetamine (MDMA)–assisted psychotherapy has been shown to greatly improve PTSD symptoms. We hypothesized that MDMA-assisted psychotherapy would improve self-reported sleep quality (SQ) in individuals with PTSD and be associated with declining PTSD symptoms.

Background
Recovery in schizophrenia is a complex process, involving clinical, societal and personal recovery. Until now, studies analysed these domains separately, without examining their mutual relations and changes over time.

Aims
This study aimed to examine different states of recovery and transition rates between states.

In “Mobile Insight in Risk, Resilience, and Online Referral (MIRROR): Psychometric Evaluation of an Online Self-Help Test” (J Med Internet Res 2020;22(9):e19716) one correction was made. This does not affect the analysis nor does it affect the interpretation or presentation of the results in the study.

In the “Methods” section, under “Measures” and “Depression, Anxiety and Stress”, the following phrase appears:

Grief disorders have recently been included in international diagnostic classifications, including the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders [DSM-5; (1)] and the 11th edition of the International Classification of Diseases [ICD-11; (2)]. Specifically, DSM-5 now includes the category “other specified trauma- and stressor-related disorder,” with persistent complex bereavement disorder as one of the specific examples, and ICD-11 includes prolonged grief disorder (PGD).